Analyst Price Targets — TSHA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 3:31 pm | Chris Raymond | Raymond James | $13.00 | $5.27 | StreetInsider | Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated' |
| January 5, 2026 12:37 pm | Zachary Fadem | Wells Fargo | $11.00 | $5.25 | TheFly | Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo |
| December 4, 2025 10:14 am | — | Goldman Sachs | $11.00 | $4.49 | TheFly | Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs |
| December 4, 2025 10:08 am | — | UBS | $11.00 | $4.49 | StreetInsider | Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy |
| November 14, 2025 12:26 pm | Kristen Kluska | Cantor Fitzgerald | $13.00 | $4.06 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA) |
| November 5, 2025 10:53 am | — | JMP Securities | $8.00 | $4.27 | TheFly | Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP |
| October 2, 2025 5:09 pm | Jack Allen | Robert W. Baird | $12.00 | $4.77 | TheFly | Taysha Gene Therapies price target raised to $12 from $7 at Baird |
| October 2, 2025 3:34 pm | Gil Blum | Needham | $10.00 | $4.77 | TheFly | Needham ups Taysha target on 'derisking' TSHA-102 news |
| August 14, 2024 10:16 am | Keith Tapper | BMO Capital | $5.00 | $2.31 | StreetInsider | BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA) |
| July 1, 2024 7:13 am | Christopher Raymond | Piper Sandler | $7.00 | $2.24 | StreetInsider | Taysha Gene Therapies (TSHA) PT Lowered to $7 at Piper Sandler |
Latest News for TSHA
DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in…
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company.
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TSHA.
U.S. House Trading
No House trades found for TSHA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.